[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Iizuka
Ryoji
R
Dept. of Surgery, Kyoto Second Red Cross Hospital.
Takahashi
Shigeru
S
Kakihara
Naoki
N
Matsumura
Hiroomi
H
Takenaka
Atsushi
A
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001202:Ascitic Fluid / Q000737:chemistry*; D004338:Drug Combinations; D005472:Fluorouracil / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005641:Tegafur / Q000008:administration & dosage* / Q000493:pharmacokinetics
C417063:5-chlorodihydroxypyridine; D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D005472:Fluorouracil